Real-World Safety And Efficacy Of The Hydrus Microstent: A Single-Centre Uk Experience

To evaluate the mid-term outcomes and safety of the Hydrus Microstent in patients treated at a UK tertiary glaucoma service.

University Hospital Southampton NHS Foundation Trust, UK.

Retrospective review of electronic records of all patients undergoing Hydrus at our trust from March 2023 to June 2025. Data was collected on demographics, diagnosis, previous glaucoma intervention and ocular co-morbidity, complications, and best-corrected visual acuity (BCVA), IOP, visual field mean deviation (VFMD) and medication use at pre-operative, week 1, months 3 and 6, one year and two years (when available). Included patients with a follow-up period of at least 6 months.

214 eyes of 171 patients with mean age 77.4±8.1 years and mean follow-up of 14.0±4.8 months were included. Most (64.0%) had primary open-angle glaucoma. 83.6% were combined with cataract surgery and 16.4% were standalone (28 pseudophakic, 4 phakic). IOP decreased significantly in standalone and combined groups, from 19.94 [95% CI 18.36, 21.51] to 15.81 [13.51, 18.12] mmHg and from 17.55 [16.90, 18.21] to 13.23 [12.70, 13.76] mmHg, respectively. Medication use fell significantly in combined cases from 2.25 [2.10, 2.41] to 1.85 [1.69, 2.00]. VFMD stabilised in both groups and BCVA improved in combined. Complications were transient and not visually significant.

Hydrus was safe and effective in improving IOP control and stabilizing visual fields in a real-world setting, as a standalone and combined procedure, with results persisting over one year.